DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Rini B.
Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.
J Clin Oncol 2011; 29
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.